Be The Investor ResearchPfizer and Edison Offer 6% Yields With Different Risks
Pfizer’s dividend is tight against free cash flow as patent losses approach, while Edison’s payout faces wildfire uncertainty. Pfizer offers the more predictable near-term risk, but neither high yield is effortless.
Pfizer and Edison International both offered yields above 6% in the source comparison. Pfizer’s cited yield was 6.3% and Edison’s 6.5%, but the pressures behind them are very different.
Pfizer’s risk is visible in cash flow. The company’s dividend used about 89% of free cash flow over the twelve months through June 28, 2026, according to TIKR. Management has said it intends to maintain the dividend, while revenue losses from patent expirations are expected to weigh on results through 2028. Pfizer raised the midpoint of its 2026 revenue outlook by $500 million in August and is pursuing additional cost savings, but dividend growth may wait until the patent cycle improves.
Edison’s accounting coverage looks stronger. Its fiscal 2025 dividend represented about 51% of normalized earnings, and 2026 core EPS guidance remained $5.90 to $6.20. Yet that measure does not capture a final value for wildfire claims.
Known erosion versus uncertain liability
Southern California Edison has said its equipment was likely associated with the Eaton Fire. The source reported $1.6 billion of settlement losses through June and additional probable losses that could not yet be estimated. Fitch later moved the outlook negative, highlighting the financing consequences of an unresolved liability.
Pfizer’s patent losses can be modeled product by product, even if the replacement pipeline and cost savings remain uncertain. Edison’s wildfire exposure is harder to bound and can affect credit ratings, borrowing costs and equity needs.
That makes Pfizer’s dividend the more predictable near-term income stream, not necessarily the stronger long-term growth asset. An 89% cash payout leaves little room if operating cash flow weakens. Edison has more payout headroom on normalized earnings, but needs a durable California liability framework and clearer claim estimates.
Investors should watch Pfizer’s free cash flow after dividend payments and Edison’s recorded wildfire losses, credit metrics and regulatory support. A high yield in either stock is compensation for risk, not evidence that the payout can grow automatically.